Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
What do you want...a medal for stating the obvious. As stated, if the directors are that confident by committing £2m of their own monies and if phase 2 looks promising, then finance will be irrelevant. I suspect that a big pharma (and I'll give you a guess who that might be) , will probably pick 4D up for a very nice premium.
Spark, you won't be getting in much cheaper so just dip your short arms into those deep pockets of yours!!!
Not calendar Q4, possibly financial Q4 but then after the readouts which is why I am invested. Even then running out does not necessarily mean fumes. They will have ops cash but possible not clinical trials cash. Fact is it’s a known unknown as opposed to a defined known and after the readouts something else may well come along.
Trek
Thank you for proving my point. The money runs out in Q4. FACT
"Money runs out in Q4. FACT"
and yet in your previouspost you said it runs out in 3 months time. I suppose one could say both statements are true but the post below gives the true picture (FACT) and the recent accounts were signed off on a "going concern" basis, meaning that the Company are confident of securing sufficient funds for the next year at least:
TrottersTrading - 01 Jul 2020 - 18:04:30 - 5202 of 5399 4D Pharma 2018 - from ?2 back up to ?10+ - DDDD
Dear Xxxxx,
Thanks for your enquiry, for clarity I have addressed each of your queries in turn.
As you may have seen earlier today the COVID-19 trial is now recruiting patients. This was updated on the official registry at http://clinicaltrial.gov (NCT04363372) yesterday but due to technical process delays was only confirmed and published today, and we will be making an announcement to confirm tomorrow morning.
We fully sympathise with your concerns regarding receipt of TR-1s. We would like to remind yourself and the investor community that the obligation is on the shareholder rather than the Company, however we are active in pursuing when we believe TR-1s have been omitted and reassure you that the Company publishes all TR-1s received in a timely manner.
Specifically regarding any TR-1s disclosing purchases corresponding to the recent disposal by Acacia, any purchasing shareholder is only obliged to provide a TR-1 if they cross the threshold of a holding of 3% or greater. As such, there is no guarantee that we should be expecting any additional TR-1s relating to the Acacia disposal. Again, we are actively pursuing this and will inform the market in a timely manner, if appropriate.
One issue we are aware of is a lack of TR-1 from South Ocean Capital relating to their participation in the February fundraising, and we are chasing and reminding the shareholder of their obligations.
Regarding the Company’s cash position, the Company is currently funded through to at least the end of 2020 during which time we expect a number of key clinical readouts including the full Phase II results for Blautix in IBS, additional data from the combination study of MRx0518 and Keytruda in cancer as well as preliminary data from our clinical biomarker study of MRx0518, and results from the COVID-19 trial, all of which we believe could be significant value inflection points for the Company and our shareholders.
I hope I have been able to address your concerns. Thank you for your continued interest and support of 4D pharma.
Regards,
Investor Relations